Enhancing Quality In Preclinical Data
7
Certified sites
18
Core Requirements
30
consortium Partners
80+
Stakeholder
Our vision
EQIPD is a fit for every member of the research community
Pharma industry
… invests into the most expensive phases of drug R&D.
Clinical studies based on preclinical evidence lacking robustness are likely to fail.
EQIPD provides solutions to improve data integrity.
Private and public funders
… support a great number of projects guided by their scientific excellence.
Research quality assessment is a filter that can be applied to focus investments on most robust and therefore more likely to translate research.
Research organizations
… increasingly depend on successful collaborations and sustainability of research output.
EQIPD offers several possibilities to review, implement and maintain best research practices.
Scientific Excellence vs. Research Quality
Scientific excellence is the key to advance science but it does not guarantee that the conducted experiments deliver robust results. There are two primary reasons for that. First, education in science does not always focus on the requirements for delivering of robust data. Second, excitement associated with a scientific hypothesis or conveyed by a scientific leader may introduce bias in study design, conduct, analysis and/or reporting.
Regulated vs. Non-regulated
In the drug discovery and development process, there are several steps that have adequate quality control and are covered by GxP policies (e.g. Good Laboratory Practice, GLP).For non-regulated areas (most specifically, biology and pharmacology of drug discovery projects), GLP-like procedures would not be fit for purpose and may not help to secure the quality of research. In fact, one may indeed imagine a lab running under GLP conditions but nevertheless still failing to design and execute robust studies.
Good Research Practice vs. Research Integrity
Responsible conduct of research has multiple facets and the examples of suboptimal or unacceptable practices go well beyond the commonly known definition of research misconduct (fabrication, falisfication or plagiarism).In addition to such direct violations of the good research practices, examples of other unacceptable practices include manipulating authorship, withholding research results, reporting of results so as to introduce or promulgate bias, failing to document essential steps or results of the research process.
EQIPD WEBINAR SERIES 2023
Kim Wever
Systematic review & meta-analysis in animal studies
The second GoEQIPD webinar on March 16, 2023 was presented by Kim Wever from Radboud University Medical Center Nijmegen discussing how systematic reviews and meta-analysis can help in translating animal study results and how they contribute to increasing robustness and scientific rigor.
Find out more about…
the EQIPD QS
the EQIPD project
Sign up for our Newsletter.
Which is published every two months and informs about developments in the field of Good Research Practice.
EQIPD Webinar Series 2023
The Guarantors of EQIPD will provide an open Webinar series in 2023 with different topics around best practices and the EQIPD Quality System.
GoEQIPD receives support by CVB
The Guarantors of EQIPD Society is honored to receive a Sponsorship grant from Cohen Veterans Bioscience, a U.S.-based 501c3 public charity to support our critical work in driving quality and reproducibility of research. CVB has supported the EQIPD Consortium from its inception and is also a Founding Member of the Society. This funding will support…
EQIPD funder tool
The Research Transparency Tool was developed by the EQIPD Consortium Taskforce and implemented online with support from a SBIR award from the NIH: https://public-funding-tool.paasp.net/survey The tool creates a “snapshot” of the environment in which research is conducted and is meant to help funders and applicants align on relevant quality expectations. More information in the EQIPD…